Two Sigma Investments LP Cuts Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Two Sigma Investments LP trimmed its holdings in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 18.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 395,907 shares of the company's stock after selling 92,228 shares during the quarter. Two Sigma Investments LP owned about 0.27% of MiMedx Group worth $3,809,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in MDXG. First Light Asset Management LLC acquired a new position in shares of MiMedx Group in the 4th quarter valued at about $32,168,000. Norges Bank bought a new stake in MiMedx Group in the 4th quarter valued at about $4,020,000. JPMorgan Chase & Co. increased its position in MiMedx Group by 133.1% in the 4th quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company's stock valued at $6,668,000 after buying an additional 395,739 shares in the last quarter. Meros Investment Management LP bought a new stake in MiMedx Group in the 4th quarter valued at about $3,801,000. Finally, Arrowstreet Capital Limited Partnership increased its position in MiMedx Group by 484.2% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company's stock valued at $3,487,000 after buying an additional 300,433 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other MiMedx Group news, CAO William Frank Iv Hulse sold 54,596 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the completion of the sale, the chief accounting officer now directly owns 440,178 shares of the company's stock, valued at approximately $3,473,004.42. The trade was a 11.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the sale, the insider now directly owns 310,836 shares of the company's stock, valued at $2,452,496.04. This represents a 1.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 141,907 shares of company stock valued at $1,112,580. Corporate insiders own 1.70% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th. Wall Street Zen lowered MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 9th.

MiMedx Group Stock Down 0.6%

MiMedx Group stock traded down $0.04 during midday trading on Monday, reaching $6.39. The stock had a trading volume of 668,198 shares, compared to its average volume of 690,677. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The company has a fifty day moving average price of $6.92 and a two-hundred day moving average price of $8.11. The company has a market capitalization of $943.82 million, a P/E ratio of 11.62 and a beta of 1.85. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, hitting analysts' consensus estimates of $0.06. The firm had revenue of $88.21 million during the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. As a group, equities analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.